Skip to main content

Biotec Pharmacon, ArcticZymes, Affymetrix Reach New Deal for Shrimp Alkaline Phosphatase

NEW YORK (GenomeWeb News) – Biotec Pharmacon today announced it has reached a new non-exclusive deal with Affymetrix for the distribution of ArcticZymes' shrimp alkaline phosphatase (SAP).

ArcticZymes is a subsidiary of Biotec Pharmacon. Affy previously had the exclusive distribution rights to SAP. The new agreement provides Affy with a long-term supply of SAP at "competitive prices" and non-exclusive rights to market, distribute, and sell the product by itself or in combination with other products for life science and diagnostic applications, Biotec said.

The new deal took effect on Sept. 23, and runs through December 2017. Financial and other terms of the agreement were not disclosed.

According to Jan Buch Anderson, managing director of Norway-based ArcticZymes, SAP remains the firm's best-selling product and provides the majority of its sales.

"We are currently building our organization and increasing our sales and marketing capabilities, and it has been very important for us to gain control over the commercial development of our SAP enzyme," he said. "Hopefully this will increase our sales and also make our revenue and earnings less volatile."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.